Business Context and Reporting Period
Company: TherapeuticsMD, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: January 8, 2019
Event: Regulation FD Disclosure (Item 7.01). The company furnished an investor presentation (Exhibit 99.1) intended for use in meetings with investors or analysts on January 8, 2019, and subsequently.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report serves solely to disclose the existence of an investor presentation and does not contain audited or unaudited financial statements within the body of the text.
Material Changes
No material changes to financial performance or operations are detailed in this specific filing text. The document references an attached presentation (Exhibit 99.1) which may contain such data, but the text of the 8-K itself does not summarize comparative period changes.
Guidance, Outlook, and Risks
Management Commentary: The filing indicates that an investor presentation was prepared for distribution to investors and analysts.
Legal Status of Information: The information furnished, including the exhibit, is not deemed "filed" under Section 18 of the Securities Exchange Act of 1934 and is not subject to the liabilities of that section. It will not be incorporated by reference into other filings unless expressly referenced.
Risks/Contingencies: No specific risks or contingencies are listed in the text of this filing.
Key Facts for Investor Verification
- Verify the contents of Exhibit 99.1 (Investor Presentation dated January 2019) for actual financial data and strategic outlook, as the 8-K text only references its existence.
- Confirm that the information in the presentation is not automatically incorporated by reference into other SEC filings.
- Note that the filing was signed by Daniel A. Cartwright, Chief Financial Officer, on January 8, 2019.